EMA recommends compassionate use of Gilead's remdesivir for COVID-19 [Yahoo! Finance News]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance News
April 3 ) - The European Medicines Agency EMA) on Friday recommended Gilead Sciences Inc's investigational antiviral drug remdesivir should be used for treating COVID-19 in compassionate use programmes.Compassionate use is the use of an unauthorised medicine outside a clinical study in individual patients under strictly-controlled conditions.The EMA said https://bit.ly/2xPfFww remdesivir has been shown to be active against the new coronavirus that causes COVID-19 in laboratory studies, but added there were limited data on its effectiveness.Remdesivir, which previously failed as an Ebola treatment, has been described by U.S. President Donald Trump and other health officials as one of the more promising candidates to fight the coronavirus."The CHMP EMA's Committee for Medicinal Products for Human Use) encourages the company to make remdesivir available in a fair and transparent way to those member States wishing to take part in international clinical trials or treat patients in compassi
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Why Is Everyone Talking About Amazon Stock? Jeff Bezos' Most Prized Possession Breaks Historical Auction Records At Almost $53 Million Analyst adjusts Nvidia stocAcquire Media Monitor
- Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramBusiness Wire
- Alcoholic Hepatitis Treatment Market To Reach USD 4.9 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- Gilead's FOCUS Program Helps Zero In on Early HIV Detection [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- GILD's page on the SEC website